Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 6
Treatment-assignment count: 0
Stratification count: 0
Trial Selection Rising
MET exon 14 skipping
melanoma · Monoclonal Antibody
MET exon 14 skipping is flagged as trial selection rising because public trials show inclusion required evidence in 6 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 2
Common snippets: MSI-H | MSI-H
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT03597282 | https://clinicaltrials.gov/study/NCT04773951 | https://clinicaltrials.gov/study/NCT06805825 | https://clinicaltrials.gov/study/NCT05483400 | https://clinicaltrials.gov/study/NCT07586891 | https://clinicaltrials.gov/study/NCT03086174